Research graph
References from Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results From 2 Phase III Studies. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1136/ard-2022-223296
10.1136/ard-2022-223296 · External reference
Axial spondyloarthritis
10.1016/s0140-6736(24)02263-3 · 2025 · External reference
2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis
10.1002/art.41042 · 2019 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.3389/fimmu.2023.1191782
10.3389/fimmu.2023.1191782 · External reference
10.1136/rmdopen-2020-001306
10.1136/rmdopen-2020-001306 · External reference
10.1136/annrheumdis-2017-212127
10.1136/annrheumdis-2017-212127 · External reference
10.1136/ard-2022-223595
10.1136/ard-2022-223595 · External reference
10.1136/ard-2023-224803
10.1136/ard-2023-224803 · External reference
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies
10.1093/rheumatology/keaf009 · 2025 · External reference
Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: three-year results from a phase IIb randomized controlled trial and its open-label extension study
10.1002/art.42282 · 2022 · External reference
10.1136/rmdopen-2024-005081
10.1136/rmdopen-2024-005081 · External reference
Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two Phase 3 studies
10.1007/s40744-024-00708-8 · 2024 · External reference
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
10.1016/s0140-6736(24)00101-6 · 2024 · External reference
Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
10.1093/bjd/ljaf032 · 2025 · External reference
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
10.1016/j.jaad.2025.04.038 · 2025 · External reference
The role of IL-17 in protection against mucosal candida infections
10.3390/jof3040052 · 2017 · External reference
10.1038/s41577-022-00746-9
10.1038/s41577-022-00746-9 · External reference
Bimekizumab in patients with non-radiographic and radiographic axial spondyloarthritis from China: 2-year results from two phase 3 studies [abstract]
2026 · External reference
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
10.1136/ard-2024-225933 · 2024 · External reference
10.1016/j.semarthrit.2021.07.021
10.1016/j.semarthrit.2021.07.021 · External reference
10.1136/annrheumdis-2022-222747
10.1136/annrheumdis-2022-222747 · External reference
